FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3083646886> ?p ?o ?g. }

• W3083646886 endingPage "2017" @default.
• W3083646886 startingPage "2017" @default.
• W3083646886 abstract "Abstract Background: Programmed death ligand 1 (PD-L1) expression on tumor cells (TC), detected by immunohistochemistry (IHC), is associated with response to programmed death-1 (PD-1)/PD-L1 inhibitors in some tumor types. Manual review of PD-L1–positive (PD-L1+) tumors can be subjective, with the potential for misclassification of PD-L1–low tumors as PD-L1–negative due to weak positivity. We compared artificial-intelligence (digital) and manual scoring methods and assessed the association of PD-L1 expression with clinical outcomes in nivolumab (NIVO)-treated patients with urothelial carcinoma (UC) and melanoma (MEL). Methods: PD-L1 expression was determined in baseline samples from NIVO monotherapy-treated patients with UC (CM275, NCT02387996) and MEL (CM067, NCT01844505; CM238, NCT02388906) using the Dako PD-L1 IHC 28-8 pharmDx assay. PD-L1+ TC were scored using digital (PathAI research platform) and manual (LabCorp) methods. Prevalence of tumors with PD-L1+ TC ≥ 1% and ≥ 5% and associations between PD-L1 expression and outcomes with NIVO were evaluated. Results: Prevalence of UC and MEL tumors with ≥ 1% and ≥ 5% PD-L1+ TC was higher for digital vs manual scoring (Table). For all samples, digital and manual scoring was associated with response to NIVO for PD-L1 ≥ 1% and ≥ 5%, and associations were similar between digital and manual scoring (Table). Digital and manual PD-L1 scoring correlated across samples from all trials (Kendall's tau range: 0.57–0.62). TablePrevalence PD-L1+ TC ≥ 1%, n (%)Evaluable samples, nDigitalManualP valueSamples ≥ 1% by digital onlyCM275241166 (69)113 (47)1.61 × 10−658 (24)CM067264173 (66)160 (61)0.27936 (14)CM238377307 (81)259 (69)7.61 × 10−566 (18)PD-L1+ TC ≥ 1% vs &lt; 1%DigitalManualORR, odds ratio (95% CI)CM275a2.15 (0.98–4.70)1.60 (0.82–3.14)CM067b1.99 (1.19–3.35)1.89 (1.12–3.18)Survival, hazard ratio (95% CI)CM275 (OS)a0.67 (0.48–0.92)0.66 (0.48–0.90)CM067 (OS)b0.57 (0.41–0.80)0.71 (0.50–1.00)CM238 (RFS)c0.53 (0.36–0.77)0.83 (0.57–1.21)Prevalence PD-L1+ TC ≥ 5%, n (%)Evaluable samples, nDigitalManualP valueSamples ≥ 5% by digital onlyCM27524190 (37)74 (31)0.14928 (12)CM067264103 (39)76 (29)0.01736 (14)CM238377234 (62)139 (37)7.54 × 10−12104 (28)PD-L1+ TC ≥ 5% vs &lt; 5%DigitalManualORR, odds ratio (95% CI)CM275a3.50 (1.76–6.98)2.37 (1.18–4.73)CM067b2.33 (1.40–3.86)1.77 (1.01–3.09)Survival, hazard ratio (95% CI)CM275 (OS)a0.50 (0.36–0.71)0.58 (0.41–0.83)CM067 (OS)b0.67 (0.47–0.96)0.74 (0.51–1.09)CM238 (RFS)c0.50 (0.35–0.70)0.52 (0.36–0.76)Database lock 2019: CM275, June 14; CM067, January 18; CM238, April 3.aAdjusted for ECOG performance status, liver metastatic status, and hemoglobin.bAdjusted for ECOG performance status, liver metastatic status, lactate dehydrogenase, and BRAF mutation.cAdjusted for ECOG performance status, AJCC stage, lactate dehydrogenase, and BRAF mutation.AJCC, American Joint Committee on Cancer; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; ORR, objective response rate; OS, overall survival; PD-L1, programmed death ligand 1; RFS, recurrence-free survival; TC, tumor cells. Conclusion: In post-hoc exploratory analyses, digital scoring of PD-L1 expression identified higher prevalence of PD-L1+ tumors and shows good association with response to NIVO in UC and MEL samples compared with manual scoring. Digital quantification demonstrated higher sensitivity at low levels of PD-L1 expression and may identify patients who could benefit from NIVO. Further study of the association with clinical outcomes is warranted and exploratory studies are ongoing to assess the performance of digital scoring in additional tumor types. Citation Format: Chunzhe Duan, Michael Montalto, George Lee, Dimple Pandya, Daniel Cohen, Han Chang, Hao Tang, Nishant Agrawal, Hunter Elliott, Benjamin Glass, Ilan Wapinski, Robin Edwards, Andrew H. Beck, Vipul Baxi. Association of digital and manual quantification of tumor PD-L1 expression with outcomes in nivolumab-treated patients [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2017." @default.
• W3083646886 created "2020-09-11" @default.
• W3083646886 creator A5004249170 @default.
• W3083646886 creator A5008634169 @default.
• W3083646886 creator A5016607688 @default.
• W3083646886 creator A5024687962 @default.
• W3083646886 creator A5025097010 @default.
• W3083646886 creator A5053487762 @default.
• W3083646886 creator A5054066760 @default.
• W3083646886 creator A5055563614 @default.
• W3083646886 creator A5059183616 @default.
• W3083646886 creator A5066737876 @default.
• W3083646886 creator A5069155531 @default.
• W3083646886 creator A5074629137 @default.
• W3083646886 creator A5079058585 @default.
• W3083646886 creator A5087653359 @default.
• W3083646886 date "2020-08-15" @default.
• W3083646886 modified "2023-10-18" @default.
• W3083646886 title "Abstract 2017: Association of digital and manual quantification of tumor PD-L1 expression with outcomes in nivolumab-treated patients" @default.
• W3083646886 doi "https://doi.org/10.1158/1538-7445.am2020-2017" @default.
• W3083646886 hasPublicationYear "2020" @default.
• W3083646886 type Work @default.
• W3083646886 sameAs 3083646886 @default.
• W3083646886 citedByCount "3" @default.
• W3083646886 countsByYear W30836468862022 @default.
• W3083646886 countsByYear W30836468862023 @default.
• W3083646886 crossrefType "journal-article" @default.
• W3083646886 hasAuthorship W3083646886A5004249170 @default.
• W3083646886 hasAuthorship W3083646886A5008634169 @default.
• W3083646886 hasAuthorship W3083646886A5016607688 @default.
• W3083646886 hasAuthorship W3083646886A5024687962 @default.
• W3083646886 hasAuthorship W3083646886A5025097010 @default.
• W3083646886 hasAuthorship W3083646886A5053487762 @default.
• W3083646886 hasAuthorship W3083646886A5054066760 @default.
• W3083646886 hasAuthorship W3083646886A5055563614 @default.
• W3083646886 hasAuthorship W3083646886A5059183616 @default.
• W3083646886 hasAuthorship W3083646886A5066737876 @default.
• W3083646886 hasAuthorship W3083646886A5069155531 @default.
• W3083646886 hasAuthorship W3083646886A5074629137 @default.
• W3083646886 hasAuthorship W3083646886A5079058585 @default.
• W3083646886 hasAuthorship W3083646886A5087653359 @default.
• W3083646886 hasConcept C121608353 @default.
• W3083646886 hasConcept C126322002 @default.
• W3083646886 hasConcept C143998085 @default.
• W3083646886 hasConcept C204232928 @default.
• W3083646886 hasConcept C2777658100 @default.
• W3083646886 hasConcept C2777701055 @default.
• W3083646886 hasConcept C2780030458 @default.
• W3083646886 hasConcept C2781053074 @default.
• W3083646886 hasConcept C502942594 @default.
• W3083646886 hasConcept C71924100 @default.
• W3083646886 hasConceptScore W3083646886C121608353 @default.
• W3083646886 hasConceptScore W3083646886C126322002 @default.
• W3083646886 hasConceptScore W3083646886C143998085 @default.
• W3083646886 hasConceptScore W3083646886C204232928 @default.
• W3083646886 hasConceptScore W3083646886C2777658100 @default.
• W3083646886 hasConceptScore W3083646886C2777701055 @default.
• W3083646886 hasConceptScore W3083646886C2780030458 @default.
• W3083646886 hasConceptScore W3083646886C2781053074 @default.
• W3083646886 hasConceptScore W3083646886C502942594 @default.
• W3083646886 hasConceptScore W3083646886C71924100 @default.
• W3083646886 hasIssue "16_Supplement" @default.
• W3083646886 hasLocation W30836468861 @default.
• W3083646886 hasOpenAccess W3083646886 @default.
• W3083646886 hasPrimaryLocation W30836468861 @default.
• W3083646886 hasRelatedWork W2478002927 @default.
• W3083646886 hasRelatedWork W2599175392 @default.
• W3083646886 hasRelatedWork W2777626578 @default.
• W3083646886 hasRelatedWork W2898986397 @default.
• W3083646886 hasRelatedWork W2947988614 @default.
• W3083646886 hasRelatedWork W2976744492 @default.
• W3083646886 hasRelatedWork W3200125437 @default.
• W3083646886 hasRelatedWork W4382538870 @default.
• W3083646886 hasRelatedWork W4382538877 @default.
• W3083646886 hasRelatedWork W4384828894 @default.
• W3083646886 hasVolume "80" @default.
• W3083646886 isParatext "false" @default.
• W3083646886 isRetracted "false" @default.
• W3083646886 magId "3083646886" @default.
• W3083646886 workType "article" @default.